๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5a replication complex inhibitor, BMS-790052

โœ Scribed by Jin-Hua Sun; Donald R. O'Boyle II; Yan Zhang; Chunfu Wang; Peter Nower; Lourdes Valera; Susan Roberts; Richard E. Nettles; Robert A. Fridell; Min Gao

Book ID
112097834
Publisher
John Wiley and Sons
Year
2012
Tongue
English
Weight
403 KB
Volume
55
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Multiple ascending dose study of BMS-790
Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1
โœ Richard E. Nettles; Min Gao; Marc Bifano; Ellen Chung; Anna Persson; Thomas C. M ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 282 KB

Abbreviations: AE, adverse event; AUC, area under the plasma concentration time curve; AUC (TAU) , AUC over 12-hour dosing interval for 30 mg twice daily; C min , minimum observed plasma concentration; C max , maximum observed plasma concentration; C trough , trough concentrations; CLT/F, apparent t

Genotypic and phenotypic analysis of var
Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in Humans: In Vitro and In Vivo Correlations
โœ Robert A. Fridell; Chunfu Wang; Jin-Hua Sun; Donald R. O'Boyle II; Peter Nower; ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 338 KB ๐Ÿ‘ 1 views

The NS5A replication complex inhibitor, BMS-790052, inhibits hepatitis C virus (HCV) replication with picomolar potency in preclinical assays. This potency translated in vivo to a substantial antiviral effect in a single-ascending dose study and a 14-day multiple-ascending dose (MAD) monotherapy stu